<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03259581</url>
  </required_header>
  <id_info>
    <org_study_id>2016LS137</org_study_id>
    <nct_id>NCT03259581</nct_id>
  </id_info>
  <brief_title>Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin</brief_title>
  <official_title>Safety of Transarterial Chemoembolization in Patients With Elevated Bilirubin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety of selective transarterial chemoembolization&#xD;
      (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but&#xD;
      relatively normal direct bilirubin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure related adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Percentage of adverse events following TACE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiologic Response</measure>
    <time_frame>1 month</time_frame>
    <description>mRECIST response after TACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1, 3, 6, 12, 18, and 24 months</time_frame>
    <description>Liver PFS and overall PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Model for end stage liver disease (MELD)</measure>
    <time_frame>7 and 30 days</time_frame>
    <description>Change in MELD (MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43) score at 7 and 30 days post TACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Child Pugh score</measure>
    <time_frame>7 and 30 days</time_frame>
    <description>Change in Child Pugh score at 7 and 30 days post TACE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Bilirubinemia</condition>
  <arm_group>
    <arm_group_label>Transarterial chemoembolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transarterial chemoembolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Transarterial chemoembolization</intervention_name>
    <description>Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.</description>
    <arm_group_label>Transarterial chemoembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Direct or conjugated bilirubin &lt; 3 mg/dl&#xD;
&#xD;
          -  Total bilirubin &gt; 3 mg/dl&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  &gt;18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Patients who are surgical or ablation candidates as determined by multidisciplinary&#xD;
             hepatobiliary tumor conference.&#xD;
&#xD;
          -  Arterial anatomy which would preclude selective transarterial chemoembolization&#xD;
&#xD;
          -  Patients who have a INR or platelet count which are not correctable to &lt;1.8 and&#xD;
             &gt;35,000 respectively&#xD;
&#xD;
          -  Patients with extrahepatic metastases&#xD;
&#xD;
          -  Patients with portal vein invasion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shamar J Young, MD</last_name>
    <phone>612-626-5388</phone>
    <email>youn1862@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Novitzke, RN</last_name>
    <phone>612-624-4865</phone>
    <email>novit001@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichole Kent</last_name>
      <phone>612-624-6904</phone>
      <email>simme033@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Shamar Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transarterial chemoembolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

